OBJECTIVES: To compare cost effectiveness of docetaxel chemotherapy with other adjuvant treatment regimens in early and locally advanced breast cancer. METHODS: Cost-effectiveness Markov model from payer perspective (health insurance and patient), using costs information from published sources and the patient lifetime horizon. RESULTS: Two comparisons, TAC (docetaxel/doxorubicin/cyclophosphamide – 75/50/500 mg/m2, 6 cycles) vs FAC (fluorouracil/doxorubicin/cyclophophamide – 500/50/500 mg/m2, 6 cycles) and FEC+T (fluorouracil/epirubicin/cyclophosphamide – 500/100/500 mg/m2, 3 cycles + docetaxel 100 mg/m2, 3 cycles) vs FEC (fluorouracil/epirubicin/cyclophosphamide – 500/100/500 mg/m2, 6 cycles), were performed. One randomized clinical trial was included for each comparison. Average costs of the treatment of early or locally advanced breast cancer (including adjuvant chemotherapy, additional treatment – tamoxifen/radiotherapy, treatment of adverse events and disease recurrence) and treatment effects were per patient: TAC 42883 PLN/25,7 LYG vs FAC 8799 PLN/23,6 LYG; FEC+T 32828 PLN/26,1 LYG vs FEC 13505 PLN/24,7 LYG. ICER for TAC vs FAC comparison was 16558 PLN/LYG. ICER for FEC+T vs FEC was 13 904 PLN/LYG. CONCLUSION: Docetaxel regimens are more effective and more expensive in the treatment of patients with early and locally advanced breast cancer compared with FAC and FEC chemotherapies, ICER range 13904-16558 PLN/LYG.